TFO
RCKT icon

Tarbox Family Office’s Rocket Pharmaceuticals RCKT Stock Holding History

Tarbox Family Office’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-49
Closed -$1K – 1127
2021
Q4 		$1K Buy
+49
New +$1.34K ﹤0.01% 1048
2021
Q2 		– Sell
-19
Closed -$1K – 1194
2021
Q1 		$1K Buy
+19
New +$1.04K ﹤0.01% 1070

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Tarbox Family Office's RCKT Position: Q1 2022 in Review

Tarbox Family Office sold out of Rocket Pharmaceuticals (RCKT) in Q1 2022, closing a stake of 49 shares — an estimated $1K sold.

Tarbox Family Office first reported a position in RCKT in Q1 2021 and held it in 2 quarters. The position peaked at $1K in Q4 2021. 149 funds tracked by Wall St. Rank hold RCKT as of Q1 2022.

  • Tarbox Family Office reported no remaining Rocket Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Tarbox Family Office sold 49 Rocket Pharmaceuticals shares in Q1 2022, an estimated $1K.
  • Tarbox Family Office first reported a position in Rocket Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Tarbox Family Office's Rocket Pharmaceuticals position peaked at $1K in Q4 2021.
  • 149 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2022.

Based on Tarbox Family Office's 13F filing for Q1 2022, filed 25 Apr 2022.